Service providers

AdaptVac

Solution provided
Technological/Validation solutions
Supplier indentity
General description
AdaptVac’s core business is the development of vaccines for infectious diseases and cancer. AdaptVac combines a highly competitive recombinant antigen production platform with a unique virus-like particle (VLP) vaccine platform. This proprietary technology is the first achieving true VLP display of large and complex antigens. The overall strength of this technology platform is the ability to develop, with a minimal effort and alteration, any recombinant vaccine candidate into a VLP particle.
Type of supplier
Biotechnology Company - Therapeutics, Lab/scientific services platform
Sector of activity:
Activity description
Services provided
AdaptVac's VLP display technology can be used in collaboration with SMEs to improve their sub-unit vaccines against infectious diseases and cancer. We can support formulation development and production and VLP display of their vaccine antigens. Furthermore, AdaptVac has access to animal facilities to test potential vaccines and adjuvants in combination with our VLP technology.
Terms of availability for SMEs
No
Quality labels and accreditations
No
Contact information
Name
Wian de Jongh
Function
CEO
Phone number
004526394649
Email address
Website
http://www.adaptvac.com
Address
Agern alle 1
2970 horsholm
Denmark

Upcoming events

29
May
iSRS 2022 - International symposium om radiopharmaceutical sciences
29 May 2022 to 02 Jun 2022NantesFrance

This conference aims to address original research in all aspects of radiopharmaceutical science; synthesis, in vitro and ex vivo studies, in vivo biodistribution or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers.

Read more

Agenda

May 2022

Mo Tu We Th Fr Sa Su
 
 
 
 
 
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
11
 
12
 
13
 
14
 
15
 
16
 
17
 
18
 
19
 
20
 
21
 
22
 
23
 
24
 
25
 
26
 
27
 
28
 
29
 
30
 
31
 
 
 
 
 
 

May 2022